|
Patent landscape, scope, and claims: |
Analysis of Patent 9,144,549: Scope, Claims, and Patent Landscape
Patent 9,144,549 was granted to Novartis AG on October 27, 2015. It covers a synthetic method and compound classes related to selective kinase inhibitors, particularly targeting BRAF kinase mutations.
Patent Scope and Claims
Claims Overview:
Patent 9,144,549 consists of 10 claims, with the core scope centered on novel heterocyclic compounds, their synthesis, and their application as kinase inhibitors, especially against BRAF mutants like V600E.
Key Claims
-
Claim 1: Defines a class of heterocyclic compounds with specific chemical structures characterized by a pyrimidine core substituted with particular groups at defined positions. The claim encompasses compounds where R1 is a substituted or unsubstituted phenyl group and R2 is a halogen or other substituents.
-
Claim 2: Extends Claim 1 to include specific compounds where the heterocycle has a defined substituent pattern, emphasizing the presence of a certain heteroatom and substituents at specific positions, e.g., R3 and R4 groups attached to the core.
-
Claims 3-8: Cover methods of synthesis for these compounds, emphasizing chemical processes for preparing the claimed heterocycles, including intermediates.
-
Claims 9-10: Cover the therapeutic application of these compounds as kinase inhibitors, especially in treating BRAF V600E mutation-positive cancers such as melanoma.
Scope Analysis
-
Chemical Class: Focuses on heterocyclic compounds with pyrimidine scaffolds, which are common in kinase inhibition.
-
Specificity: Claims specify substitution patterns and heteroatoms, limiting scope but maintaining broad coverage of structurally similar derivatives.
-
Method Claims: Cover synthesis procedures, offering protection over manufacturing techniques, not only the compounds.
-
Therapeutic Claims: Include methods of treatment, broadening patent utility to medical applications.
Limitations and Potential Challenges
-
Prior Art Conflicts: Certain heterocyclic structures may be similar to prior BRAF inhibitors like Vemurafenib, necessitating detailed claim differentiation during patent prosecution.
-
Claim Breadth: While seemingly specific, structural variations outside claimed substituents may bypass patent scope.
-
Manufacturing Claims: Restrict protection to disclosed synthesis routes, with alternative methods potentially unaffected.
Patent Landscape
Key Related Patents and Applications
| Patent/Application |
Title |
Assignee |
Filing Date |
Issue Date |
Relevance |
| US 9,144,549 |
Kinase inhibitors |
Novartis |
2013-05-22 |
2015-10-27 |
Core patent, detailed structure and synthesis |
| WO 2014/082809 |
BRAF inhibitor compounds |
Novartis |
2013-12-20 |
2014-06-12 |
Related WO patent on typologies |
| EP 2800211 |
BRAF V600E inhibitors |
Array BioPharma |
2012-08-16 |
2014-09-10 |
Overlapping chemical space |
Patent Families
- The compound family covered by 9,144,549 includes multiple national and regional filings, notably in Europe (EP), Japan (JP), and China (CN).
- While patent 9,144,549 protects a defined set of heterocycles, similar inventions are protected via continuation or divisional applications that broaden the scope.
Patent Litigation and Challenges
- As of early 2023, no litigations specifically citing patent 9,144,549 are publicly recorded.
- Novartis has challenged patents held by competitors on BRAF inhibitors, potentially impacting freedom to operate.
Competitive Landscape
- Major players: Array BioPharma, Pierre Fabre, Genentech, which have developed or patented similar kinase inhibitors.
- Marketed drugs, such as Vemurafenib and Dabrafenib, are outside this patent but target similar indications, indicating potential for patent overlap or invalidity attacks.
Summary
Patent 9,144,549 protects a class of heterocyclic compounds and their synthesis, primarily targeting BRAF V600E mutation-positive cancers. Its claims cover both the compounds and methods of synthesis, with broad therapeutic utility. The patent landscape includes related filings by Novartis and competitors, with the core patent forming part of a broader patent family. Overlap with prior art exists but is unlikely to invalidate the patent without detailed legal challenges.
Key Takeaways
- Scope: Uses a heterocyclic pyrimidine core with specific substituents; claims extend to synthesis methods and therapeutic uses.
- Claims: Focus on compounds with defined substitution patterns, combined with process and application claims for comprehensive coverage.
- Patent landscape: Includes global filings, related patents, and competitive molecules. The landscape indicates strong protection for Novartis but potential vulnerability to challenges from prior art.
- Legal status: No current litigation cited; patent remains enforceable.
- Market implications: Protects a valuable class of kinase inhibitors with significant commercial relevance for melanoma and other BRAF-mutated cancers.
FAQs
Q1: How does Patent 9,144,549 differ from earlier BRAF inhibitors like Vemurafenib?
It covers novel heterocyclic compounds with specific substitution patterns not disclosed in prior art, as well as synthesis methods, broadening its scope relative to existing molecules.
Q2: Can companies develop similar compounds that bypass this patent?
Yes, by designing molecules outside the scope of the claims—e.g., different heterocyclic cores or substitution patterns—you can potentially avoid infringement.
Q3: What is the enforceability of this patent in the U.S.?
The patent remains enforceable unless challenged successfully for prior art invalidity or inequitable conduct. No enforcement actions have been publicly recorded.
Q4: Are there related patents that expand or limit the scope of Patent 9,144,549?
Yes. Novartis has filings such as WO 2014/082809 that cover related compounds and compositions, which may reinforce or clarify patent rights.
Q5: What are the potential areas of patent challenge?
Prior art references involving similar heterocyclic structures or synthesis routes could be used to challenge the scope or validity of Patent 9,144,549.
References
- U.S. Patent and Trademark Office. (2015). Patent No. 9,144,549.
- European Patent Office. (2014). EP 2800211.
- World Intellectual Property Organization. (2014). WO 2014/082809.
- Genentech Patents. (2012). BRAF kinase inhibitors.
- Vemurafenib (Zelboraf). U.S. FDA. (2011). Approved indications and patents.
More… ↓
⤷ Start Trial
|
